Magnesium and kidney stones: a concise narrative review

Clicks: 2
ID: 323551
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #51 of 125 articles by views in clinical kidney journal

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 125 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Magnesium is a potentially relevant factor in kidney stone disease (KSD), particularly in calcium-containing stones. This narrative review summarizes magnesium metabolism, its anti-lithogenic mechanisms, and the current evidence on supplementation in KSD. Magnesium may reduce stone risk through intestinal oxalate binding, inhibition of calcium oxalate crystallization, and increased urinary citrate excretion. A systematic search of PubMed, Web of Science, and Embase (up to April 2026) identified interventional and observational studies evaluating magnesium and urinary or clinical outcomes. Study quality was assessed using the GRADE framework, and the review followed SANRA guidance. Fifteen studies were included, comprising metabolic studies, observational analyses, and four randomized controlled trials. Observational studies consistently report an inverse association between urinary magnesium and stone risk. Interventional studies show improvements in urinary parameters, including increased magnesium and citrate excretion and reduced oxalate, particularly when taken with meals. However, randomized evidence remains limited and heterogeneous. Current evidence does not support routine magnesium supplementation over established therapies such as potassium citrate. Nevertheless, magnesium, especially citrate-containing formulations, may be considered in selected patients, including those with hypomagnesuria, hypocitraturia, or intolerance to potassium salts. Larger, high-quality randomized trials are needed.
Reference Key
openalex_W7172411301 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Martin Scoglio, Matteo Bargagli, Daniel G. Fuster
Journal clinical kidney journal
Year 2026
DOI
10.1093/ckj/sfag248
URL
https://doi.org/10.1093/ckj/sfag248
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.